Superworth

Keros Therapeutics profit margin KROS

Gross, operating and net profit as a share of revenue over the last twelve months, from 2025.

Net margin, 12 months
n/m
not a meaningful number
Peer median
13.6%

Keros Therapeutics' net margin works out at −554% over the last twelve months, but it is not a meaningful number: a margin outside minus 100% to 100% is moved by items that are not sales.

Profit margin over time

OperatingNet

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearNet marginOperating margin
FY202535.7%27.7%
FY2024n/an/a
FY2023n/an/a
FY2022n/an/a
FY2021n/an/a
FY2020n/an/a
FY2019n/an/a

Quarter by quarter

QuarterEndedNet margin, 12 monthsChange on a yearOperating margin
Q2 FY26n/an/an/a
Q1 FY26n/an/an/a
Q4 FY2535.7%n/a27.7%
Q3 FY2526.1%n/a17.7%
Q2 FY258.1%n/a0.1%
Q1 FY252.0%n/a−4.8%
Q4 FY24n/an/an/a
Q3 FY24n/an/an/a
Q2 FY24n/an/an/a
Q1 FY24n/an/an/a
Q4 FY23n/an/an/a
Q3 FY23n/an/an/a

Against its peers

Companies in Drug Manufacturers - General nearest Keros Therapeutics' size, closest first, today.

CompanyProfit margin
KROSKeros Therapeuticsn/m
NATRNatures Sunshine Products3.7%
ARVNArvinas2.9%
PBYIPuma Biotechnology11.6%
IRWDIronwood Pharmaceuticals33.4%
ZVRAZevra Therapeutics42.8%
CRMDCorMedix40.5%
LFVNLifevantage2.8%
COLLCollegium Pharmaceutical5.9%
SPROSpero Therapeutics15.7%
ABUSArbutus Biopharma84.2%
Peer median13.6%

What the profit margin tells you

Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).

Compare within an industry. 10% is superb for a retailer and poor for a software company.

More on Keros Therapeutics

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.